icon-folder.gif   Conference Reports for NATAP  
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
2019 April 10-14
Vienna Austria
Back grey_arrow_rt.gif
Real-World Health Care Resource Utilizati on and Quality of Life With Glecaprevir/Pibrentasvir Treatment: A Pooled Analysis From Post-Marketing Observational Studies
  Reported by Jules Levin
EASL 10-14 April 2019, Vienna, Austria
Alessio Aghemo1, Stefan Bourgeois2, Michael Gschwantler3, Yuri Sanchez Gonzalez4, Lois Larsen4, Mark Bondin4, Rawi Hazzan5, Lorenzo Magenta6, Tarik Asselah7 1Humanitas University and Research Hospital, Rozzano, Italy; 2Department of Gastroenterology and Hepatology, ZNA Antwerp, Antwerp, Belgium; 3Department of Internal Medicine IV, Wilhelminenspital, and Sigmund Freud University, Vienna, Austria; 4AbbVie, Inc., North Chicago, Illinois, United States; 5Emek Medical Center, Afula, Israel; 6Epatocentro Ticino, Lugano, Switzerland; 7Hopital Beaujon & INSERM UMR 1149, Clichy, France